Single-cell Exome Sequencing and Monoclonal Evolution of a JAK2-negative Myeloproliferative Neoplasm
Overview
Authors
Affiliations
Tumor heterogeneity presents a challenge for inferring clonal evolution and driver gene identification. Here, we describe a method for analyzing the cancer genome at a single-cell nucleotide level. To perform our analyses, we first devised and validated a high-throughput whole-genome single-cell sequencing method using two lymphoblastoid cell line single cells. We then carried out whole-exome single-cell sequencing of 90 cells from a JAK2-negative myeloproliferative neoplasm patient. The sequencing data from 58 cells passed our quality control criteria, and these data indicated that this neoplasm represented a monoclonal evolution. We further identified essential thrombocythemia (ET)-related candidate mutations such as SESN2 and NTRK1, which may be involved in neoplasm progression. This pilot study allowed the initial characterization of the disease-related genetic architecture at the single-cell nucleotide level. Further, we established a single-cell sequencing method that opens the way for detailed analyses of a variety of tumor types, including those with high genetic complex between patients.
SCGclust: Single Cell Graph clustering using graph autoencoders integrating SNVs and CNAs.
Potu T, Hu Y, Khan R, Dharani S, Ni J, Zhang L bioRxiv. 2025; .
PMID: 39975167 PMC: 11838312. DOI: 10.1101/2025.01.28.635357.
Zhang W, Zhang X, Teng F, Yang Q, Wang J, Sun B Genes Dis. 2024; 12(1):101239.
PMID: 39552788 PMC: 11566696. DOI: 10.1016/j.gendis.2024.101239.
Mugen-UMAP: UMAP visualization and clustering of mutated genes in single-cell DNA sequencing data.
Li T, Zou Y, Li X, Wong T, Rodrigo A BMC Bioinformatics. 2024; 25(1):308.
PMID: 39333868 PMC: 11437917. DOI: 10.1186/s12859-024-05928-x.
Cai J, Zhang W, Lu Y, Liu W, Zhou H, Liu M Signal Transduct Target Ther. 2024; 9(1):247.
PMID: 39307879 PMC: 11417107. DOI: 10.1038/s41392-024-01960-8.
Resolving tumor evolution: a phylogenetic approach.
Li L, Xie W, Zhan L, Wen S, Luo X, Xu S J Natl Cancer Cent. 2024; 4(2):97-106.
PMID: 39282584 PMC: 11390690. DOI: 10.1016/j.jncc.2024.03.001.